Summary of findings table ‐ Daratumumab plus standard therapy vs usual care
Health‐related quality of life European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30). Scale from: 0 to 100 (a higher score means a better outcome) · people with newly diagnosed multiple myeloma ineligible for transplant
1 finding from 1 review
- Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple… 2024 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 1096 participantsLow